Prof. Dr. med. Stefan Lüth

Prof. Dr. med. Stefan Lüth
Klinikdirektor

Klinikdirektor und Chefarzt
Hochschulkoordinator

Telefon: (03381) 41 16 00
E-Mail: s.lueth@uk-brandenburg.de


Telefon: (03381) 41 16 00
Publikationen

  1. Eosinophil Counts in Mucosal Biopsies of the Ileum and Colon: Interobserver Variance Affects Diagnostic Accuracy.

    Hentschel F, Jansen AF, Günther M, Pauli R, Lüth S.
    Patholog Res Int. 2018 Nov 4;2018:2638258. doi: 10.1155/2018/2638258. eCollection 2018.

  2. Outcome and clinical course of EHEC O104 infection in hospitalized patients: A prospective single center study.

    Albersmeier JP, Bremer JP, Dammermann W, Lüth S, Hagenmüller F, Rüther C, Otto H, Nielsen AM, Schumacher U, Ullrich S.
    PLoS One. 2018 Feb 8;13(2):e0191544. doi: 10.1371/journal.pone.0191544. eCollection 2018.

  3. Anti-Shiga toxin 2 antibodies in enterohemorrhagic Escherichia coli O104:H4 infected patients may predict hemolytic uremic syndrome.

    Dammermann W, Mihajlov V, Middendorf B, Mellmann A, Karch H, Lüth S, Ullrich S.
    J Gastroenterol Hepatol. 2018 Jul;33(7):1353-1356. doi: 10.1111/jgh.14082. Epub 2018 Mar 12.

  4. Chronic pancreatitis in patients with liver cirrhosis negatively affects graft survival after liver transplantation.

    Wehmeyer MH, Dammermann W, Seiz O, Zinser ME, Galante A, Lohse AW, Sterneck M, Nashan B, Herden U, Lüth S.
    Pancreatology. 2017 Nov - Dec;17(6):898-904. doi: 10.1016/j.pan.2017.09.006. Epub 2017 Sep 14.

  5. Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.

    Dammermann W, Polywka S, Dettmann I, Mindorf S, Komorowski L, Wehmeyer M, Schulze Zur Wiesch J, Stöcker W, Lüth S.
    Med Microbiol Immunol. 2017 Oct;206(5):379-382. doi: 10.1007/s00430-017-0516-z. Epub 2017 Aug 16.

  6. CpG oligonucleotides increase HBV-specific cytokine responses in whole blood and enhance cytokine release assay sensitivity.

    Dammermann W, Dornbrack J, Bröker K, Bentzien F, Lüth S.
    J Virol Methods. 2017 Oct;248:195-201. doi: 10.1016/j.jviromet.2017.07.011. Epub 2017 Jul 21.

  7. Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients.

    Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C, Chen PJ, Peng CY, Chang TT, Lueth S, De Knegt R, Choi MS, Wedemeyer H, Dao M, Kim CW, Chu HC, Wind-Rotolo M, Williams R, Cooney E, Chokshi S.
    Front Immunol. 2017 May 29;8:621. doi: 10.3389/fimmu.2017.00621. eCollection 2017.

  8. High clinical manifestation rate in an imported outbreak of hepatitis E genotype 1 infection in a German group of travellers returning from India.

    Pischke S, Schulze-Zur-Wiesch J, Lütgehetmann M, Kreuels B, Lueth S, Kapaun P, Benten D, Schmiedel S, Sterneck M, Lohse AW, Polywka S.
    Ann Hepatol. 2017 Jan-Feb;16(1):57-62. doi: 10.5604/16652681.1226815.

  9. A Proinflammatory Role of Type 2 Innate Lymphoid Cells in Murine Immune-Mediated Hepatitis.

    Neumann K, Karimi K, Meiners J, Voetlause R, Steinmann S, Dammermann W, Lüth S, Asghari F, Wegscheid C, Horst AK, Tiegs G.
    J Immunol. 2017 Jan 1;198(1):128-137. Epub 2016 Nov 21.

  10. Exacerbation of hepatitis E virus infection during anti-TNFα treatment.

    Behrendt P, Lüth S, Dammermann W, Drave S, Brown RJ, Todt D, Schnoor U, Steinmann E, Wedemeyer H, Pischke S, Iking-Konert C.
    Joint Bone Spine. 2017 Mar;84(2):217-219. doi: 10.1016/j.jbspin.2016.09.017. Epub 2016 Nov 8.

  11. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.

    Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S.
    World J Gastroenterol. 2016 Mar 28;22(12):3418-31. doi: 10.3748/wjg.v22.i12.3418.

  12. Clinical Management of Ebola Virus Disease in the United States and Europe.

    Uyeki TM, Mehta AK, Davey RT Jr, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grünewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AI, Gutman J; Working Group of the U.S.–European Clinical Network on Clinical Management of Ebola Virus Disease Patients in the U.S. and Europe.
    N Engl J Med. 2016 Feb 18;374(7):636-46. doi: 10.1056/NEJMoa1504874.

  13. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.

    Wiegand SB, Heidrich B, Susser S, Rogalska-Taranta M, Petersen J, Böker KH, Grigorian N, Link R, Naumann U, John C, Lueth S, Malfertheiner P, Manns MP, Wedemeyer H, Sarrazin C, Cornberg M.
    PLoS One. 2015 Dec 23;10(12):e0145622. doi: 10.1371/journal.pone.0145622. eCollection 2015.

  14. Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity.

    Deterding K, Grüner N, Buggisch P, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Grohennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H, Wiegand J; Hep-Net Acute HCV-III Study Group.
    Eur J Gastroenterol Hepatol. 2016 Feb;28(2):187-92. doi: 10.1097/MEG.0000000000000517.

  15. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

    Karimova M, Beschorner N, Dammermann W, Chemnitz J, Indenbirken D, Bockmann JH, Grundhoff A, Lüth S, Buchholz F, Schulze zur Wiesch J, Hauber J.
    Sci Rep. 2015 Sep 3;5:13734. doi: 10.1038/srep13734.

  16. Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.

    Wehmeyer MH, Jordan S, Lüth S, Hartl J, Stoehr A, Eißing C, Lohse AW, Petersen J, Buggisch P, Schulze Zur Wiesch J.
    Dig Liver Dis. 2015 Sep;47(9):811-4. doi: 10.1016/j.dld.2015.05.018. Epub 2015 May 24.

  17. Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients.

    Dammermann W, Bentzien F, Stiel EM, Kühne C, Ullrich S, Schulze Zur Wiesch J, Lüth S.
    J Transl Med. 2015 May 13;13:157. doi: 10.1186/s12967-015-0513-1.

  18. Association of hepatitis E virus and essential cryoglobulinemia?

    Pischke S, Polywka S, Haag F, Iking-Konert C, Sterneck M, Lütgehetmann M, Dammermann W, Lüth S, Schirmer JH.
    J Clin Virol. 2015 Jun;67:23-4. doi: 10.1016/j.jcv.2015.03.020. Epub 2015 Mar 28. No abstract available.

  19. High Rate of Cardiac Abnormalities in a Postmortem Analysis of Patients Suffering From Liver Cirrhosis.

    Wehmeyer MH, Heuer AJ, Benten D, Püschel K, Sydow K, Lohse AW, Lüth S.
    J Clin Gastroenterol. 2015 Nov-Dec;49(10):866-72. doi: 10.1097/MCG.0000000000000323.

  20. Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure.

    Bockmann JH, Dandri M, Lüth S, Pannicke N, Lohse AW.
    World J Gastroenterol. 2015 Feb 21;21(7):2214-9. doi: 10.3748/wjg.v21.i7.2214.

  21. Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice.

    Carambia A, Freund B, Schwinge D, Bruns OT, Salmen SC, Ittrich H, Reimer R, Heine M, Huber S, Waurisch C, Eychmüller A, Wraith DC, Korn T, Nielsen P, Weller H, Schramm C, Lüth S, Lohse AW, Heeren J, Herkel J.
    J Hepatol. 2015 Jun;62(6):1349-56. doi: 10.1016/j.jhep.2015.01.006. Epub 2015 Jan 21.

  22. CMV specific cytokine release assay in whole blood is optimized by combining synthetic CMV peptides and toll like receptor agonists.

    Dammermann W, Bochmann D, Bentzien F, Komorowski L, Steinhagen K, Ullrich S, van Lunzen J, Lüth S.
    J Immunol Methods. 2014 Dec 1;414:82-90. doi: 10.1016/j.jim.2014.10.011. Epub 2014 Oct 30.

  23. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection.

    Roeder C, Jordan S, Schulze Zur Wiesch J, Pfeiffer-Vornkahl H, Hueppe D, Mauss S, Zehnter E, Stoll S, Alshuth U, Lohse AW, Lueth S.
    World J Gastroenterol. 2014 Aug 21;20(31):10984-93. doi: 10.3748/wjg.v20.i31.10984.

  24. Anti-HDV IgM as a marker of disease activity in hepatitis delta.

    Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group.
    PLoS One. 2014 Jul 29;9(7):e101002. doi: 10.1371/journal.pone.0101002. eCollection 2014.

  25. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.

    Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S; EMERGE study group.
    J Hepatol. 2014 Dec;61(6):1238-46. doi: 10.1016/j.jhep.2014.07.022. Epub 2014 Jul 24.

  26. German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients.

    Beisel C, Heuer M, Otto B, Jochum J, Schmiedel S, Hertling S, Degen O, Lüth S, van Lunzen J, Schulze Zur Wiesch J.
    AIDS Res Ther. 2014 Jul 1;11:16. doi: 10.1186/1742-6405-11-16. eCollection 2014.

  27. Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.

    Wehmeyer MH, Eißing F, Jordan S, Röder C, Hennigs A, Degen O, Hüfner A, Hertling S, Schmiedel S, Sterneck M, van Lunzen J, Lohse AW, Schulze zur Wiesch J, Lüth S.
    BMC Gastroenterol. 2014 May 5;14:87. doi: 10.1186/1471-230X-14-87.

  28. Prevention of hemolytic uremic syndrome with daily bowel lavage in patients with Shiga toxin-producing enterohemorrhagic Escherichia coli O104:H4 infection.

    Lüth S, Fründt TW, Rösch T, Schlee C, Lohse AW.
    JAMA Intern Med. 2014 Jun;174(6):1003-5. doi: 10.1001/jamainternmed.2014.1175. No abstract available.

  29. Prediction of spontaneous bacterial peritonitis in cirrhotic ascites by a simple scoring system.

    Wehmeyer MH, Krohm S, Kastein F, Lohse AW, Lüth S.
    Scand J Gastroenterol. 2014 May;49(5):595-603. doi: 10.3109/00365521.2013.848471. Epub 2014 Mar 27.

  30. Laparoscopic Heller myotomy versus endoscopic balloon dilatation for the treatment of achalasia: a network meta-analysis.

    Schoenberg MB, Marx S, Kersten JF, Rösch T, Belle S, Kähler G, Vassiliou MC, Lüth S, von Renteln D.
    Ann Surg. 2013 Dec;258(6):943-52. doi: 10.1097/SLA.0000000000000212.

  31. Viral hepatitis in alcohol-dependent inpatients: prevalence, risk factors, and treatment uptake.

    Schmidt CS, Schön D, Schulte B, Lüth S, Polywka S, Reimer J.
    J Addict Med. 2013 Nov-Dec;7(6):417-21. doi: 10.1097/ADM.0b013e3182a50817.

  32. Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection.

    Dammermann W, Schipper P, Ullrich S, Fraedrich K, Schulze Zur Wiesch J, Fründt T, Tiegs G, Lohse A, Lüth S.
    PLoS One. 2013 Sep 23;8(9):e74880. doi: 10.1371/journal.pone.0074880. eCollection 2013.

  33. Toll like receptor 2 agonists lipoteichoic acid and peptidoglycan are able to enhance antigen specific IFNγ release in whole blood during recall antigen responses.

    Dammermann W, Wollenberg L, Bentzien F, Lohse A, Lüth S.
    J Immunol Methods. 2013 Oct 31;396(1-2):107-15. doi: 10.1016/j.jim.2013.08.004. Epub 2013 Aug 15.

  34. Infiltration of peritumoural but tumour-free parenchyma with IgG4-positive plasma cells in hilar cholangiocarcinoma and pancreatic adenocarcinoma.

    Resheq YJ, Quaas A, von Renteln D, Schramm C, Lohse AW, Lüth S.
    Dig Liver Dis. 2013 Oct;45(10):859-65. doi: 10.1016/j.dld.2013.03.007. Epub 2013 Apr 19.

  35. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.

    Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H; Hep-Net Acute HCV-III Study Group.
    Lancet Infect Dis. 2013 Jun;13(6):497-506. doi: 10.1016/S1473-3099(13)70059-8. Epub 2013 Mar 22.

  36. A novel flexible cryoprobe for EUS-guided pancreatic biopsies.

    von Renteln D, Quaas A, Rösch T, Denzer UW, Szyrach MN, Enderle MD, Lüth S, Haas S, Trepte C, Reutter D, Schachschal G.
    Gastrointest Endosc. 2013 May;77(5):784-92. doi: 10.1016/j.gie.2012.12.013. Epub 2013 Feb 27.

  37. [A 44-year-old woman with hereditary nonpolyposis colon carcinoma: screening examinations for non-colonic tumors].

    Holzhüter J, Rösch T, Block A, Lohse AW, Lüth S.
    Internist (Berl). 2013 Mar;54(3):353-8. doi: 10.1007/s00108-012-3224-1. German.

  38. Telaprevir for retreatment of HCV infection.

    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team.
    N Engl J Med. 2011 Jun 23;364(25):2417-28. doi: 10.1056/NEJMoa1013086.

  39. Chronic inflammatory IFN-γ signaling suppresses hepatocarcinogenesis in mice by sensitizing hepatocytes for apoptosis.

    Lüth S, Schrader J, Zander S, Carambia A, Buchkremer J, Huber S, Reifenberg K, Yamamura K, Schirmacher P, Lohse AW, Herkel J.
    Cancer Res. 2011 Jun 1;71(11):3763-71. doi: 10.1158/0008-5472.CAN-10-3232. Epub 2011 Apr 21.

  40. "Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.

    Schulze Zur Wiesch J, Pudelski N, Hoepner L, Supplieth M, Buggisch P, Lohse AW, Lüth S.
    Hepatology. 2011 Apr;53(4):1405-6; author reply 1407. doi: 10.1002/hep.24185. No abstract available.

  41. [ALT screening for chronic liver diseases: scrutinizing the evidence].

    Wedemeyer H, Hofmann WP, Lueth S, Malinski P, Thimme R, Tacke F, Wiegand J.
    Z Gastroenterol. 2010 Jan;48(1):46-55. doi: 10.1055/s-0028-1109980. Epub 2010 Jan 13. Review. German.

  42. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis.

    Denzer UW, Lüth S.
    Best Pract Res Clin Gastroenterol. 2009;23(3):453-60. doi: 10.1016/j.bpg.2009.03.002. Review.

  43. Activin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells.

    Huber S, Stahl FR, Schrader J, Lüth S, Presser K, Carambia A, Flavell RA, Werner S, Blessing M, Herkel J, Schramm C.
    J Immunol. 2009 Apr 15;182(8):4633-40. doi: 10.4049/jimmunol.0803143.

  44. [Autoimmune liver diseases].

    Lüth S, Weiler-Normann C, Schramm C, Lohse AW.
    Internist (Berl). 2009 Mar;50(3):310-7. doi: 10.1007/s00108-008-2254-1. Review. German.

  45. P38 MAP kinase signaling is required for the conversion of CD4+CD25- T cells into iTreg.

    Huber S, Schrader J, Fritz G, Presser K, Schmitt S, Waisman A, Lüth S, Blessing M, Herkel J, Schramm C.
    PLoS One. 2008 Oct 1;3(10):e3302. doi: 10.1371/journal.pone.0003302.

  46. Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs.

    Lüth S, Huber S, Schramm C, Buch T, Zander S, Stadelmann C, Brück W, Wraith DC, Herkel J, Lohse AW.
    J Clin Invest. 2008 Oct;118(10):3403-10. doi: 10.1172/JCI32132.

  47. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome.

    Lüth S, Kanzler S, Frenzel C, Kasper HU, Dienes HP, Schramm C, Galle PR, Herkel J, Lohse AW.
    J Clin Gastroenterol. 2009 Jan;43(1):75-80. doi: 10.1097/MCG.0b013e318157c614.

  48. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis.

    Lüth S, Herkel J, Kanzler S, Frenzel C, Galle PR, Dienes HP, Schramm C, Lohse AW.
    J Clin Gastroenterol. 2008 Sep;42(8):926-30. doi: 10.1097/MCG.0b013e318154af74.

  49. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis.

    Frenzel C, Herkel J, Lüth S, Galle PR, Schramm C, Lohse AW.
    Am J Gastroenterol. 2006 Dec;101(12):2731-6.

  50. Multiplex neuritis in a patient with autoimmune hepatitis: a case report.

    Luth S, Birklein F, Schramm C, Herkel J, Hennes E, Muller-Forell W, Galle PR, Lohse AW.
    World J Gastroenterol. 2006 Sep 7;12(33):5396-8.

  51. Transgenic overproduction of murine 60 kDa heat shock protein in the liver does not prevent type I diabetes in NOD mice.

    Lüth S, Lohse AW, Herkel J.
    Diabetologia. 2006 May;49(5):1123-4. Epub 2006 Mar 18. No abstract available.

  52. Autoimmune hepatitis.

    Lueth S, Lohse AW.
    Clin Med (Lond). 2006 Jan-Feb;6(1):25-8. Review. No abstract available.

  53. Hepatic over-expression of TGF-beta1 promotes LPS-induced inflammatory cytokine secretion by liver cells and endotoxemic shock.

    Garcia-Lazaro JF, Thieringer F, Lüth S, Czochra P, Meyer E, Renteria IB, Galle PR, Lohse AW, Herkel J, Kanzler S.
    Immunol Lett. 2005 Nov 15;101(2):217-22.

  54. Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusions.

    Kuball J, Theobald M, Ferreira EA, Hess G, Burg J, Maccagno G, Barreiros AP, Lüth S, Schimanski CC, Schuchmann M, Schwarting A, Neurath M, Otto G, Galle PR, Lohse AW.
    Transplantation. 2004 Dec 27;78(12):1774-9.

  55. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.

    Herkel J, Jagemann B, Wiegard C, Lazaro JF, Lueth S, Kanzler S, Blessing M, Schmitt E, Lohse AW.
    Hepatology. 2003 May;37(5):1079-85.

  56. Fecal elastase-1 determination: 'gold standard' of indirect pancreatic function tests?

    Lüth S, Teyssen S, Forssmann K, Kölbel C, Krummenauer F, Singer MV.
    Scand J Gastroenterol. 2001 Oct;36(10):1092-9.

  57. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.

    Lüth S, Teyssen S, Kölbel CB, Singer MV.
    Z Gastroenterol. 2001 Apr;39(4):279-81, 284-5.

ZURÜCK